Benyettou F., Lalatonne Y., Sainte-Catherine O., Lecouvey M., Motte L.
Laboratoire CSPBAT FRE 3043 CNRS, FR
Keywords: Bisphosphonate, Cancer drugs, drug nanoparticle, drug targeting, magnetic nanoparticle
We designed a new therapeutic nanoplatform which could be both imaged in situ with MRI (T2 contrast agent) and/or addressed by magnetic targeting (magnet) or specific molecules (peptides, antibodies …). The biological in-vitro tests performed on breast cancer cell line, MDA-MB 231, showed that free alendronate and Fe2O3@Alendronate have similar antiproliferative activity. In addition, we showed that the particles penetrate in cells by endocytosis uptake. Preliminary results of tests in vivo on nude mice show that Fe2O3@Alendronate has antiproliferative properties on breast cancer tumours. Indeed, under a magnetic field, we observed a significant slowdown of the tumours growth for Fe2O3@Alendronate treated mices whereas the free Alendronate molecules have no effect on the tumour growth.
Journal: TechConnect Briefs
Volume: 2, Nanotechnology 2009: Life Sciences, Medicine, Diagnostics, Bio Materials and Composites
Published: May 3, 2009
Pages: 40 - 43
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology
ISBN: 978-1-4398-1783-4